Adult Dosing

Hypovolemic shock

• Usual minimum effective dose: 250-500 mL IV PRN
• Adjust the rate of infusion according to the clinical response and rising blood pressure
• Administered by IV infusion at a site at some distance from any site of infection or trauma
• Monitor patients for signs of hypervolemia, including dyspnea, fluid in the lungs, and abnormal increases in blood pressure or central venous pressure

Pediatric Dosing

• Safety and effectiveness in the pediatric population have not been established

[Outline]

• Adult Dosing
• Pediatric Dosing

• Treatment of shock due to burns, crushing injuries, abdominal emergencies, and any other cause where there is a significant loss of plasma fluids
• Emergency treatment of shock due to hemorrhage
• Initial treatment of shock in infants and small children due to dehydration and infection

• Hypersensitivity to any of the ingredients of the product
• Cardiopulmonary bypass
• Severe anemia
• Congestive heart failure
• Increased blood volume

• N/A

Renal Dose Adjustment

• Renal impairment: Dose adjustments not defined; use with caution

Hepatic Dose Adjustment

• Hepatic impairment: Dose adjustments not defined; use with caution

• Products made from human plasma may contain infectious agents, such as viruses and Creutzfeldt-Jakob Disease (CJD) agent that can cause disease. The risk of transmission of an infectious agent may be reduced by screening plasma donors for prior exposure to certain viruses, by testing for the presence of certain current virus infections, and by inactivating and/or removing certain viruses
• Signs and symptoms of certain viral infections, particularly hepatitis C, may develop in individuals who receive infusions of blood or plasma products
• Risks and benefits of this product should be discussed with the patient before prescribing or administering it
• Avoid using turbid or frozen solution of blood or plasma products
• Do not begin administration >4 hrs after the container has been entered; discard partially used vials
• Rapid infusion of this product may produce hypotension in patients undergoing surgery or in the preoperative or postoperative period. Monitor blood pressure during therapy; slow or stop infusion if sudden hypotension occurs
• Plasma protein fraction does not provide coagulation factors and therefore does not correct coagulation disorders

Caution: Use cautiously in

• Renal failure
• Hepatic failure
• Large doses
• Dehydration
• Low cardiac reserve

Pregnancy Category:C

Breastfeeding: Safety unknown.

• CV: Hypotension
• CNS: Headache
• GI: Nausea
• DERM: Flushing, urticaria
• MUSC: Back pain

• Plasma volume expander; increases colloid osmotic pressure within the intravascular space equal to human plasma; shifts water from extravascular tissues back into the intravascular space, thereby expanding plasma volume
• Metabolism: Unknown
• Excretion: Unknown
• Half-life: Unknown

US Trade Name(s)

• Plasmanate

US Availability

Plasmanate

• INJ: 50 mg/mL

Canadian Trade Name(s)

• N/A

Canadian Availability

• N/A

UK Trade Name(s)

• N/A

UK Availability

• N/A

Australian Trade Name(s)

• N/A

Australian Availability

• N/A

[Outline]

Cardiovascular

Plasma Expanders

Emergency/Critical Care

Plasma Expanders